Regeneron Pharmaceuticals, Inc. (1REGN)
MTA
649.80
-2.50 (-0.38%)
Closed
Oct 2, 2026
Day's Range
649.80659.80
52 wk Range
467.50723.50
Financial Statements - 1REGN - Regeneron Pharmaceuticals, Inc.
Revenue
14.34B▲ 19.7%
Net Income
4.50B▲ 21.0%Net Margin 31.4%
EBITDA
4.99B▲ 13.9%
Free Cash Flow
3.76B▲ 26.1%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 14.34B | 11.97B | 13.11B | 12.17B | 16.07B | 8.49B |
| Cost of Goods | 2.10B | 1.66B | 1.81B | 1.56B | 2.43B | 1.11B |
| Gross Profit | 12.24B | 10.31B | 11.30B | 10.61B | 13.63B | 7.37B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 3.70B | 3.36B | 4.23B | 4.99B | 8.99B | 3.57B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 855.70M | 112.18M | -456.80M | -235.90M | 342.50M | 290.70M |
| Pre Tax Income | 5.23B | 4.03B | 4.19B | 4.85B | 9.32B | 3.81B |
| Income Tax | 725.80M | 309.82M | 245.70M | 520.40M | 1.25B | 297.20M |
| Net Income | 4.50B | 3.72B | 3.95B | 4.33B | 8.07B | 3.51B |
| EPS Basic | 43.07 | 40.9 | 37.05 | 40.51 | 76.399998 | 32.649999 |
| EPS Diluted | 41.48 | 38.34 | 34.77 | 38.22 | 71.969999 | 30.519999 |
| Basic Shares Outstanding | 104.60M | 91.01M | 111.04M | 111.46M | 110M | 111.98M |
| Diluted Shares Outstanding | 104.60M | 91.01M | 111.04M | 111.46M | 110M | 111.98M |
| Ebit | 5.27B | 4.07B | 4.27B | 4.91B | 9.38B | 3.86B |
| Ebitda | 4.99B | 4.38B | 5.13B | 5.50B | 9.33B | 4.10B |
| Net Income Continuous Operations | 4.50B | 3.72B | 3.95B | 4.33B | 8.07B | 3.51B |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
